#1 ProtocolClav's Stack
−28.7%Weight Loss Data
24+Peptides Available
>98%HPLC Purity
$200+Free Shipping
ApolloVerified Supplier
Back to Products
CJC-1295 No DAC 10mg

Research Specifications

Components:
CJC-1295 No DAC (Mod GRF 1-29) + Ipamorelin
CJC-1295 No DAC MW:
3367.9 Da
Ipamorelin MW:
711.9 Da
Form:
Lyophilized powder blend
Purity:
≥98% each component (HPLC verified)
Storage:
−20°C long-term / 4°C up to 4 weeks reconstituted
Reconstitution:
Bacteriostatic water

CJC-1295 No DAC 10mg

CJC-1295 (No DAC) + Ipamorelin — pre-blended GHRH analog and ghrelin receptor agonist. Synergistic GH secretagogue combination for amplified pulsatile growth hormone release.

$79.99In Stock
Buy Now
>98% Purity Lyophilized Powder Fast Shipping

Dual-Pathway GH Secretagogue: GHRH-R + GHS-R1a

This combination pairs CJC-1295 No DAC (a GHRH analogue, also known as Mod GRF 1-29) with Ipamorelin (a selective ghrelin receptor agonist). CJC-1295 No DAC binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and secretion with a ~30 minute half-life that preserves pulsatile GH release. Ipamorelin (CAS: 170851-70-4) selectively activates GHS-R1a (ghrelin receptor) — a completely different receptor from the GHRH receptor. Dual-receptor activation is additive: combined GH release substantially exceeds either compound alone. Ipamorelin does not stimulate cortisol, prolactin, or ACTH release at research doses — unlike GHRP-2 or GHRP-6. The No DAC formulation's ~30 minute half-life preserves physiological pulsatile GH patterns vs the 6–8 day half-life of DAC-modified CJC-1295.

Research Highlights

Dual Receptor Synergy

GHRH receptor activation (CJC-1295) and ghrelin receptor activation (Ipamorelin) signal through different G-protein pathways (Gs and Gq respectively). Co-activation of both pathways in pituitary somatotrophs produces substantially greater GH pulse amplitude than either alone — the pharmacological rationale for the pre-blended combination.

Ipamorelin Selectivity

Ipamorelin activates GHS-R1a with high selectivity, producing GH release without significant cortisol, ACTH, or prolactin elevation. Unlike GHRP-2 and GHRP-6, Ipamorelin does not produce measurable off-target hormone stimulation at research doses, making it the preferred ghrelin mimetic for clean GH secretagogue protocols.

Pulsatile GH Preservation (No DAC)

The No DAC formulation of CJC-1295 has a ~30 minute half-life, allowing natural GH pulse rhythm to be maintained. The DAC modification extends half-life to 6–8 days, producing continuous GH elevation that blunts natural pulsatility. No DAC is specifically chosen for research requiring physiological GH pulsatile patterns.

Research FAQ

What is the difference between CJC-1295 No DAC and with DAC?
CJC-1295 No DAC has ~30 minute half-life and produces discrete GH pulses. CJC-1295 with DAC has a Drug Affinity Complex modification enabling albumin binding, extending half-life to ~8 days for sustained GH elevation. No DAC better preserves physiological GH pulsatility.
Why combine CJC-1295 with Ipamorelin?
GHRH receptor agonists (CJC-1295) and ghrelin receptor agonists (Ipamorelin) activate two independent intracellular pathways. This dual stimulation of pituitary somatotrophs produces substantially greater GH pulse amplitude than either compound alone.
Does Ipamorelin elevate cortisol?
Unlike GHRP-6 and GHRP-2, Ipamorelin is highly selective for GHS-R1a and does not significantly elevate ACTH or cortisol at research doses. This selectivity makes it the preferred ghrelin receptor agonist for clean GH secretagogue research.

Research Use Only. This product is intended for in-vitro laboratory research only. Not for human consumption, injection, or therapeutic use. Not medical advice. Always consult applicable regulations in your jurisdiction.

CJC-1295 No DAC 10mg

$79.99

Buy Now